A computational platform combining language-model guidance with mechanistic prioritization identified interleukin-15 as a cytokine enhancer for glypican-3 CAR-T in antigen-low liver cancer. The work frames IL-15 as a way to improve CAR-T potency where target expression is insufficient for robust killing. In gastric cancer, early clinical signals from the satri-cel phase I program suggest durable peritoneal disease control in three advanced cases with high claudin 18.2 expression. The report notes benefit in patients with peritoneal metastasis, including one case enabling conversion surgery and long-term peritoneal control. Taken together, the two studies span preclinical optimization and first-in-human evidence—both centered on maximizing efficacy in difficult tumor settings defined by antigen limitation or anatomically challenging peritoneal disease.
Get the Daily Brief